Obudai Egeszsegugyi Centrum Kft

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Obesity2 trials
• Atrial fibrillation1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting1 trial
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Amgen1 trial
• Anthos Therapeutics, Inc.1 trial
• Eli Lilly and Company1 trial

Running trials

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

  NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting

Closed trials

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source